Marketers of nutritional supplements often complain that they do not know what the FDA wants. Even after the agency sends a warning letter about misleading claims and advertising, its staff does not explain what would fall within the rules. That’s the reality; the FDA will tell you what’s wrong, not what’s right.
Through warning letters, the [...]
David Frum could have lowered his rhetorical blood pressure in his CNN.com guest commentary on the evils of dietary supplement marketing by reading the FTC regulations that go into effect on Tuesday. His column then would have begun: The party is over Dec. 1.
Two days of hearings before the FDA about search-based advertising for drugs produced one possible solution: fixed warnings for products. Google has proposed that its AdWords could include a hyperlinked line that warns consumers about the potential dangers of a drug.
On Nov. 12, drugmakers and search-engine advertising agencies participated in about 30 presentations before the FDA. The hearing room was so crowded that most people seeking an audience seat were turned away. What did the company executives say?
Should there be a language standard in Google ads for supplements? Drug marketers may adopt rules given the close scrutiny that the FDA is giving search-generated ads for pharmaceuticals. It may also be time for makers and marketers to set rules what is allowed.
The Web has erupted with news, opinion and practical guidance on the new FTC rules that apply to disclosures on blogger freebies. As a public service, NutriSupLaw offers a sampling of the best of initial analysis.
